Drugs / ETX0282
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03491748 | Mar 2018 → Sep 2019 | — | Entasis Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETX0282 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03491748 ↗ |
| Route | Oral | “single oral dose of 100 milligrams (mg) ETX0282 or placebo” NCT03491748 ↗ |